BioTime will report earnings from Q4 on March 7. Analysts predict BioTime will release losses per share of $0.043. Go here to track BioTime stock price in real-time on Markets Insider. BioTime ...
ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE MKT and TASE: BTX), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today reported financial ...
. The LOI contains broad terms of a potential transaction through which Geron would contribute to BAC its intellectual property and other assets related to Geron's discontinued human embryonic stem ...
ALAMEDA, Calif., Feb. 14, 2019 (GLOBE NEWSWIRE) -- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today provided a business update which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback